Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATARI: Abatacept as Adjuvant to Peanut Oral Immunotherapy
NCT04872218Phase 2Completed
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in peanut allergy. Started Mar 2022; status: completed.
02
Drugs
abatacept
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT04872218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872218.